CytomX to Present at Cowen and Company’s 36th Annual Health Care Conference
2016年3月10日 - 9:46AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced that it will present at Cowen
and Company’s 36th Annual Health Care Conference in Boston. Sean
McCarthy, D.Phil., chief executive officer, will deliver a
corporate overview at 10:40 a.m. EST on Tuesday, March 8.
A live audio webcast of the presentation will be available
through the Investors and News section of CytomX's website. An
archived replay will be available for 90 days following the
event.
About CytomX Therapeutics
CytomX is an oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The company uses the
platform to create development-stage proprietary cancer
immunotherapies against clinically-validated targets, as well as to
develop first-in-class investigational cancer therapeutics against
novel targets. CytomX believes that its Probody platform has the
potential to improve the combined efficacy and safety profile of
monoclonal antibody modalities, including cancer immunotherapies,
antibody drug conjugates and T-cell-recruiting bispecific
antibodies. Probody therapeutics are designed to take advantage of
unique conditions in the tumor microenvironment to enhance the
tumor-targeting features of an antibody and reduce drug activity in
healthy tissues. Investigational Probody therapeutics are being
developed that address clinically-validated cancer targets in
immuno-oncology, such as PD-L1, against which clinical candidate
CX-072 is directed, as well as novel targets, such as CD-166, that
are difficult to drug without causing damage to healthy tissues, or
toxicities. In addition to its proprietary programs, CytomX is
collaborating with strategic partners including Bristol-Myers
Squibb Company, Pfizer Inc., MD Anderson Cancer Center, and
ImmunoGen, Inc. For more information, visit www.cytomx.com.
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements. Our Probody platform is in
preclinical development, and the process by which a preclinical
technology could potentially lead to an approved product is long
and subject to significant risks and uncertainties. Applicable
risks and uncertainties include those relating to our preclinical
research and development and other risks identified under the
heading "Risk Factors" included in our filings with the SEC. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Corporate Communications Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024